Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quebec races to meet cancer demand - tech spend ahead at Laval:

This article was originally published in Clinica

Executive Summary

Quebec's race against increasing cancer incidence levels is behind its Can$28.7m (US$24m) investment in a new 6,000 square metre oncology centre at the Hopital Cite de la Sante in the south-western city of Laval. However, this amount will not cover high-tech equipment, which will require further funding. The centre, which is expected to be ready by 2010, will feature six treatment rooms containing four linear accelerators (with two more due to be installed at a later date). Cancer levels in Quebec are rising by almost 1,000 cases per year. This year, 39,000 cases are expected, according to Canadian Healthcare Technology, which also reports that Can$36.3m was recently pledged for a new cancer treatment centre at Maisonneuve-Rosemont Hospital in Montreal.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT047572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel